Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 39.11% is 469% above its 5-year average of 6.87%, near the high end of its 5-year range (-79.95%–46.56%).
8.39% below its 12-month average of 42.69%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 45.07%.
EBITDA MARGIN
39.11%
EBITDA MARGIN AVG TTM
42.69%
EBITDA MARGIN AVG 3Y
35.03%
EBITDA MARGIN AVG 5Y
6.87%
EBITDA MARGIN AVG 10Y
-94.60%
EBITDA MARGIN AVG 15Y
-139.57%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-8.39%
CURRENT VS 3Y AVG
+11.65%
CURRENT VS 5Y AVG
+469.33%
CURRENT VS 10Y AVG
+141.34%
CURRENT VS 15Y AVG
+128.02%
CURRENT VS 20Y AVG
N/A
ADMA Biologics, Inc.
Market Cap
$2.38B
EBITDA Margin
39.11%
TTM Avg
42.69%
3Y Avg
35.03%
5Y Avg
6.87%
Market Cap
$2.38B
EBITDA Margin
-37.02%
TTM Avg
-37.02%
3Y Avg
-37.02%
5Y Avg
-37.02%
Market Cap
$2.36B
EBITDA Margin
-317.71%
TTM Avg
-346.77%
3Y Avg
-338.06%
5Y Avg
-349.04%
Market Cap
$2.40B
EBITDA Margin
-4.36%
TTM Avg
-3.80%
3Y Avg
-12.43%
5Y Avg
-17.77%
Market Cap
$2.34B
EBITDA Margin
-31.49%
TTM Avg
-441.22%
3Y Avg
-377.50%
5Y Avg
-1549.50%
Market Cap
$2.42B
EBITDA Margin
-755.79%
TTM Avg
-753.93%
3Y Avg
-709.93%
5Y Avg
-1157.85%
Market Cap
$2.30B
EBITDA Margin
26.92%
TTM Avg
28.50%
3Y Avg
31.74%
5Y Avg
29.80%
Market Cap
$2.28B
EBITDA Margin
29.14%
TTM Avg
-19.91%
3Y Avg
8.86%
5Y Avg
26.54%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | $2.38B | 39.11% | 42.69% | 35.03% | 6.87% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.38B | -37.02% | -37.02% | -37.02% | -37.02% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.36B | -317.71% | -346.77% | -338.06% | -349.04% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | -4.36% | -3.80% | -12.43% | -17.77% |
| Liquidia Corporation (LQDA)vs › | $2.34B | -31.49% | -441.22% | -377.50% | -1549.50% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.42B | -755.79% | -753.93% | -709.93% | -1157.85% |
| Disc Medicine, Inc. (IRON)vs › | $2.45B | N/A | N/A | N/A | N/A |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.30B | 26.92% | 28.50% | 31.74% | 29.80% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.28B | 29.14% | -19.91% | 8.86% | 26.54% |
| Privia Health Group, Inc. (PRVA)vs › | $2.58B | 2.08% | 1.74% | 1.01% | -2.48% |
Gross Margin
64.7%
EBITDA Margin
39.1%
Operating Margin
42.3%
Net Margin
33.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 45.07% |
| 2026-03-31 | 45.53% |
| 2025-12-31 | 46.56% |
| 2025-09-30 | 39.51% |
| 2025-06-30 | 36.77% |
| 2025-03-31 | 32.10% |
| 2024-12-31 | 34.26% |
| 2024-09-30 | 34.69% |
| 2024-06-30 | 38.48% |
| 2024-03-31 | 29.23% |
| 2023-12-31 | 22.11% |
| 2023-09-30 | 16.02% |
| 2023-06-30 | 2.70% |
| 2023-03-31 | 2.14% |
| 2022-12-31 | -8.25% |
| 2022-09-30 | -18.14% |
| 2022-06-30 | -21.97% |
| 2022-03-31 | -45.44% |
| 2021-12-31 | -44.25% |
| 2021-09-30 | -62.93% |
| 2021-06-30 | -79.95% |
| 2021-03-31 | -86.83% |
| 2020-12-31 | -114.56% |
| 2020-09-30 | -124.22% |
| 2020-06-30 | -208.51% |
| 2020-03-31 | -156.68% |
| 2019-12-31 | -58.14% |
| 2019-09-30 | -113.98% |
| 2019-06-30 | -160.53% |
| 2019-03-31 | -351.50% |
| 2018-12-31 | -385.16% |
| 2018-09-30 | -305.99% |
| 2018-06-30 | -269.97% |
| 2018-03-31 | -388.49% |
| 2017-12-31 | -75.67% |
| 2017-09-30 | -287.39% |
| 2017-06-30 | -239.00% |
| 2017-03-31 | -221.35% |
| 2016-12-31 | -114.99% |
| 2016-09-30 | -123.20% |
| 2016-06-30 | -236.60% |
| 2016-03-31 | -190.22% |
| 2015-12-31 | -159.76% |
| 2015-09-30 | -245.42% |
| 2015-06-30 | -259.48% |
| 2015-03-31 | -205.26% |
| 2014-12-31 | -242.63% |
| 2014-09-30 | -218.47% |
| 2014-06-30 | -235.87% |
| 2014-03-31 | -361.13% |
| 2013-12-31 | -1053.39% |
| 2013-09-30 | -223.61% |
| 2013-06-30 | -643.45% |
| 2013-03-31 | -391.77% |
| 2012-12-31 | -420.22% |
| 2012-09-30 | -888.03% |
| 2012-06-30 | -504.32% |
| 2012-03-31 | -26540.16% |
